Appeal No. 1997-2167
Application 08/137,444
Thereafter in the paragraph bridging pages 673 and 674, the
authors observe that:
Galanthamine (1, scheme 1), a long-acting, centrally-
active competitive cholinesterase inhibitor, has shown
considerable promise. This natural product, an alkaloid
of the Amaryllidaceae family, is hydrolysis-resistant,
only moderately toxic, and more readily absorbed than
physostigmine. The animal data suggest that this compound
might be effective in treating the central cholinergic
deficits in Alzheimer's disease. A recent clinical trial
found that 1 was a well-tolerated drug during long term
treatment. [cites to the bibliography omitted]3
On page 674 the parent compound 1 and nine other galanthamine
derivatives are set forth. On page 679 in Table III, the
IC 's for seven galanthamine derivatives is set forth and in
50
vivo studies were conducted on galanthamine n-butyl carbamate
in mice and yielded "promising results".
Additionally, the examiner has cited several other
references in support of his rejection which acknowledge the
role of AChE inhibitors in treating Alzheimer's disease. See
for example, Robinson et al. at page 1127 wherein the authors
Whether or not the results of the clinical trial have3
been published and whether, if published, the results are
prior art having a bearing on the patentability of the
appealed claims is an issue the examiner and appellants should
investigate upon return of this application to the examining
group.
13
Page: Previous 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next
Last modified: November 3, 2007